Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database

Tau PET imaging: present and future directions

(2017) Laure Saint-Aubert et al.   Molecular Neurodegeneration

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

(2016) Philip S.J. Weston et al.   JOURNAL OF ALZHEIMERS DISEASE

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

(2016) Panagiotis Alexopoulos et al.   Alzheimers Research & Therapy

Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment

(2016) Sepideh Shokouhi et al.   Alzheimers Research & Therapy

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment

(2016) Marina Boccardi et al.   JAMA Neurology

Florbetapir positron emission tomography and cerebrospinal fluid biomarkers

(2015) Ann Hake et al.   Alzheimers & Dementia

Measurement of Longitudinal  -Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios

(2015) S. M. Landau et al.   JOURNAL OF NUCLEAR MEDICINE

Improved Power for Characterizing Longitudinal Amyloid-  PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region

(2015) K. Chen et al.   JOURNAL OF NUCLEAR MEDICINE

Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction

(2015) Matthias Brendel et al.   NEUROIMAGE

Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes

(2015) Stefanie Schreiber et al.   JAMA Neurology

Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease

(2015) Jon B. Toledo et al.   JAMA Neurology

Extension and refinement of the predictive value of different classes of markers in ADNI: Four-year follow-up data

(2014) Jesus J. Gomar et al.   Alzheimers & Dementia

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study

(2014) Kevin T Ong et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

(2014) P M Doraiswamy et al.   MOLECULAR PSYCHIATRY

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

(2014) Niklas Mattsson et al.   Annals of Clinical and Translational Neurology

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

(2013) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Amyloid imaging and memory change for prediction of cognitive impairment

(2013) Susan M Resnick et al.   Alzheimers Research & Therapy

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease

(2012) S. Duke Han et al.   Brain Imaging and Behavior

A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease

(2012) Agneta Nordberg et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Amyloid-  Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods

(2012) S. M. Landau et al.   JOURNAL OF NUCLEAR MEDICINE

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

(2011) Stephen D. Weigand et al.   Alzheimers & Dementia

Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

(2011) Adam S. Fleisher   ARCHIVES OF NEUROLOGY

CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects

(2011) M. Ewers et al.   CEREBRAL CORTEX

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease

(2011) Michael J Pontecorvo et al.   Alzheimers Research & Therapy

Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease

(2010) K.B. Walhovd et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

(2010) Geert De Meyer   ARCHIVES OF NEUROLOGY

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

(2010) C. R. Jack et al.   BRAIN

Comparing predictors of conversion and decline in mild cognitive impairment

(2010) S. M. Landau et al.   NEUROLOGY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

(2009) John C. Morris et al.   ARCHIVES OF NEUROLOGY

Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B

(2009) Martha Storandt et al.   ARCHIVES OF NEUROLOGY

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Reducing between scanner differences in multi-center PET studies

(2009) Aniket Joshi et al.   NEUROIMAGE

Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study

(2009) A. Okello et al.   NEUROLOGY

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY

Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly

(2008) Howard Jay Aizenstein et al.   ARCHIVES OF NEUROLOGY